Your browser doesn't support javascript.
loading
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari, Carmelo; Pascale, Maria Rosaria; Vitale, Antonio; Diral, Elisa; Tomelleri, Alessandro; Galossi, Elisa; Falconi, Giulia; Bruno, Alessandro; Crisafulli, Francesca; Frassi, Micol; Cattaneo, Chiara; Bertoli, Diego; Bernardi, Massimo; Condorelli, Annalisa; Morsia, Erika; Poloni, Antonella; Crisà, Elena; Caravelli, Daniela; Triggianese, Paola; Brussino, Luisa; Battipaglia, Giorgia; Bindoli, Sara; Sfriso, Paolo; Caroni, Federico; Dragani, Matteo; Mallegni, Flavia; Pilo, Federica; Firinu, Davide; Curti, Antonio; Papayannidis, Cristina; Olivieri, Attilio; Kordasti, Sharham; Albano, Francesco; Pane, Fabrizio; Musto, Pellegrino; Bocchia, Monica; Lugli, Elisabetta; Breccia, Massimo; Frigeni, Marco; Dagna, Lorenzo; Greco, Raffaella; Franceschini, Franco; Campochiaro, Corrado; Cantarini, Luca; Voso, Maria Teresa.
Afiliación
  • Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Pascale MR; Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
  • Vitale A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Diral E; Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy.
  • Tomelleri A; Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Galossi E; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy.
  • Falconi G; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Bruno A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Crisafulli F; Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Frassi M; ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
  • Cattaneo C; ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
  • Bertoli D; ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
  • Bernardi M; ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
  • Condorelli A; Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Morsia E; Azienda SocioSanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Poloni A; Hematology Department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
  • Crisà E; Hematology Department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
  • Caravelli D; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Triggianese P; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Brussino L; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Battipaglia G; Department of Medical Sciences Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy.
  • Bindoli S; Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  • Sfriso P; Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy.
  • Caroni F; Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy.
  • Dragani M; Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
  • Mallegni F; IRCCS San Martino Hospital, Genova, Italy.
  • Pilo F; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Firinu D; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Curti A; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Papayannidis C; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Olivieri A; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Kordasti S; Hematology Department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
  • Albano F; Hematology Department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
  • Pane F; Haematology, Guy's Hospital & Comprehensive Cancer Centre, King's College, London, UK.
  • Musto P; Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University, Bari, Italy.
  • Bocchia M; Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  • Lugli E; Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University, Bari, Italy.
  • Breccia M; Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
  • Frigeni M; Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Dagna L; Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy.
  • Greco R; Azienda SocioSanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Franceschini F; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy.
  • Campochiaro C; Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cantarini L; ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
  • Voso MT; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy.
Am J Hematol ; 99(2): 254-262, 2024 02.
Article en En | MEDLINE | ID: mdl-38108611
ABSTRACT
VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow-up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Enfermedades Cutáneas Genéticas / Síndromes Mielodisplásicos / Leucemia / Trasplante de Células Madre Hematopoyéticas Límite: Aged / Humans / Male Idioma: En Revista: Am J Hematol Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Enfermedades Cutáneas Genéticas / Síndromes Mielodisplásicos / Leucemia / Trasplante de Células Madre Hematopoyéticas Límite: Aged / Humans / Male Idioma: En Revista: Am J Hematol Año: 2024 Tipo del documento: Article País de afiliación: Italia